Effect of Glutamine Dipeptide Supplementation on Primary Outcomes for Elective Major Surgery: Systematic Review and Meta-Analysis

Nutrients

Marta Sandini¹  Luca Nespoli¹  Massimo Oldani¹  Davide Paolo Bernasconi² 

[1] Department of Surgery and Translational Medicine, Milano-Bicocca University, San Gerardo Hospital (4° piano A), via Pergolesi 33, 20900 Monza, Italy; E-Mails:;Department of Health Sciences, Center of Biostatistics for Clinical Epidemiology, Milano-Bicocca University, 20900 Monza, Italy; E-Mail:

关键词: glutamine;    dipeptide;    surgery;    outcome;    infections;    meta-analysis;   

DOI  :  10.3390/nu7010481

来源: mdpi

【 摘 要 】

To evaluate if glutamine (GLN) supplementation may affect primary outcomes in patients undergoing major elective abdominal operations, we performed a systematic literature review of randomized clinical trials (RCTs) published from 1983 to 2013 and comparing intravenous glutamine dipeptide supplementation to no supplementation in elective surgical abdominal procedures. A meta-analysis for each outcome (overall and infectious morbidity and length of stay) of interest was carried out. The effect size was estimated by the risk ratio (RR) or by the weighted mean difference (WMD). Nineteen RCTs were identified with a total of 1243 patients (640 receiving GLN and 603 controls). In general, the studies were underpowered and of medium or low quality. GLN supplementation did not affect overall morbidity (RR = 0.84, 95% CI 0.51 to 1.36; p = 0.473) and infectious morbidity (RR = 0.64; 95% CI = 0.38 to 1.07; p = 0.087). Patients treated with glutamine had a significant reduction in length of hospital stay (WMD = −2.67; 95% CI = −3.83 to −1.50; p < 0.0001). In conclusion, GLN supplementation appears to reduce hospital stay without affecting the rate of complications. The positive effect of GLN on time of hospitalization is difficult to interpret due to the lack of significant effects on surgery-related morbidity.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.